文献速递胸部肿瘤

NY-ESO-1和XAGE1血清抗体预测NSCLC抗PD-1治疗反应

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-08-23

该前瞻性研究探讨NY-ESO-1和/或XAGE1癌症睾丸抗原血清抗体能否预测NSCLC患者抗PD-1治疗的临床反应和生存。发现队列13例中6例抗体阳性者均响应,验证队列75例中17例抗体阳性者客观缓解率65%显著高于阴性者19%(p=0.0006),且无进展生存和总生存显著延长。多因素分析仅抗体阳性是PFS(HR=0.4,p=0.01)和OS(HR=0.2,p=0.004)的显著预测因素。

要点

  • 抗体阳性者客观缓解率65% vs 阴性者19%(p=0.0006)
  • 抗体阳性是PFS(HR=0.4)和OS(HR=0.2)的独立预测因素
  • 抗体预测价值独立于PD-L1表达、突变负荷和CD8+ T细胞浸润

核心结论

  • NY-ESO-1和/或XAGE1血清抗体是预测NSCLC抗PD-1治疗临床获益的有用生物标志物。

研究设计与样本

  • 前瞻性研究,发现队列13例NSCLC患者,验证队列75例NSCLC患者。
  • 血清抗体用酶联免疫吸附试验检测,肿瘤免疫微环境和突变负荷分别用免疫组化和二代测序分析。

主要发现

  • 发现队列中6例抗体阳性者均响应抗PD-1治疗(2例完全缓解,4例部分缓解),7例抗体阴性者均未响应。
  • 验证队列中17例抗体阳性者客观缓解率65%,58例阴性者19%(p=0.0006),抗体阳性者无进展生存和总生存显著延长。
  • 抗体滴度与肿瘤缩小率高度相关。
  • 多因素分析中,肿瘤PD-L1表达和抗体阳性是反应生物标志物,但仅抗体阳性是PFS(HR=0.4,p=0.01)和OS(HR=0.2,p=0.004)的显著更好预测因素。

关键数值与推荐

  • 验证队列抗体阳性者客观缓解率65% vs 阴性者19%(p=0.0006)。
  • 抗体阳性预测PFS的HR=0.4(p=0.01),预测OS的HR=0.2(p=0.004)。

临床怎么用

  • 可考虑检测NY-ESO-1和XAGE1血清抗体以筛选可能从抗PD-1治疗中获益的NSCLC患者。
  • 抗体阳性者即使PD-L1表达阴性、突变负荷低或CD8+ T细胞浸润少,仍可能从抗PD-1治疗中获益。

局限性

  • 发现队列样本量小(n=13),验证队列样本量中等(n=75)。
  • 研究为前瞻性但非随机,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti-PD-1 therapy have yet to be identified; therefore, predictive biomarkers are needed to select patients with benefits. METHODS: We conducted a prospective study to explore whether serum antibody against NY-ESO-1 and/or XAGE1 cancer-testis antigens predicted primarily good clinical response and secondarily long survival with anti-PD-1 therapy for NSCLC. The serum antibody was detected by enzyme-linked immunosorbent assay, and tumor immune microenvironment and mutation burden were analyzed by immunohistochemistry and next-generation sequencing. RESULTS: In the discovery cohort (n = 13), six antibody-positive NSCLC cases responded to anti-PD-1 therapy (two complete and four partial responses), whereas seven antibody-negative NSCLC cases did not. Antibody positivity was associated with good response and survival, regardless of tumor programmed death ligand 1 (PD-L1) expression, mutation burden, and CD8+ T-cell infiltration. In the validation cohort (n = 75), 17 antibody-positive NSCLC cases responded well to anti-PD-1 therapy as compared with 58 negative NSCLC cases (objective response rate 65% versus 19%, p = 0.0006) and showed significantly prolonged progression-free survival and overall survival. Antibody titers highly correlated with tumor reduction rates. In the multivariate analysis, response biomarkers were tumor programmed death ligand 1 expression and antibody positivity, and only antibody positivity was a significantly better predictive biomarker of progression-free survival (hazard ratio = 0.4, p = 0.01) and overall survival (hazard ratio = 0.2, p = 0.004). CONCLUSIONS: Our results suggest that NY-ESO-1 and/or XAGE1 serum antibodies are useful biomarkers for predicting clinical benefits in anti-PD-1 therapy for NSCLC and probably for other cancers.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ohue Y, Kurose K, Karasaki T, et al. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. J Thorac Oncol. 2019. PMID: 31449889. doi:10.1016/j.jtho.2019.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。